The 90% effective dose (ED90) of esketamine for inhibiting responses to intraoperative motor stimulation during ambulatory hysteroscopy: a biased-coin up-and-down sequential allocation trial.

BACKGROUND

Esketamine and remimazolam co-administration presents a viable opioid-free anesthetic alternative for outpatient hysteroscopy. This study was designed to ascertain the ED90 of esketamine for inhibiting intraoperative movement responses in patients undergoing ambulatory hysteroscopy.

METHODS

From February 2024 to May 2024, 50 patients undergoing ambulatory hysteroscopy were enrolled. An anesthetic regimen combining esketamine and remimazolam with 50 mg flurbiprofen axetil was employed. The initial esketamine dose was 0.3 mg/kg, with subsequent doses determined using a biased-coin design (9:1). The primary endpoint was the ED90 of esketamine for inhibiting movement responses. Secondary outcomes included anesthesia recovery time, Visual Analog Scale (VAS) scores, and adverse events.

RESULTS

The ED90 of esketamine was 0.405 mg/kg (95% CI: 0.370–0.494). Mean anesthesia recovery time was 12.1 ± 2.0 min. No respiratory depression, hypertension, hypotension, or bradycardia occurred. Mild dizziness was observed in 38% of patients; other adverse events (postoperative nausea and vomiting 4%, coughing 4%, hiccups 4%, transient diplopia 2%) resolved spontaneously. Postoperative VAS scores ranged from 0 to 4 at PACU admission (4% reporting 4), decreasing to 0–1 within four hours.

CONCLUSIONS

In ambulatory hysteroscopy under remimazolam-based anesthesia with preemptive analgesia using flurbiprofen axetil, the ED90 of esketamine required to suppress intraoperative body movement was 0.405 mg/kg (95% CI: 0.370–0.494).